Скачать или смотреть The Science behind EASE | India's First Medically Approved tES Device

Can mental health treatment be both portable and safe?
For decades, psychiatry has relied on two main routes: medication and psychotherapy. These remain the cornerstones of care. But medications can cause unwanted side effects, and therapy alone may not always be enough.

Ease builds on this foundation.
Ease is a CDSCO-approved neuromodulation device that delivers gentle, non-invasive brain stimulation to the dorsolateral prefrontal cortex (DLPFC)—areas of the brain that regulate mood, focus, and emotional balance.

🔹 Research in India: In a 2024 clinical trial, over 50% of patients with treatment-resistant depression improved after two weeks of tDCS sessions. At one month, 77% maintained their response.

🔹 Global evidence: A meta-analysis of 23 randomized, sham-controlled trials found that active tDCS significantly outperformed sham treatment in depression outcomes. Specifically, the response rate was 33.3% for active tDCS compared to 16.56% for sham, and the remission rate was 19.12% for active tDCS compared to 9.78% for sham.

Why this matters for India:
With just 1 psychiatrist for every 100,000 people, access to care remains a challenge. Ease offers:

A safe, non-drug intervention that works alongside medication and therapy
Portable technology that brings treatment beyond the clinic
Real-time EEG monitoring to personalize care for every individual

Ease is not an alternative to psychiatry, it’s an ally in advancing mental health care.

🌐 Learn more on our website: www.marbles.health